Secondary diseases and Burkitt’s lymphoma in HIV-infected patients

Abstract


The authors give the clinical data of 110 human immunodeficiency virus (HIV)-infected patients who stayed in a correctional facility during 2014. Of the examinees, there were almost 50% of the patients with advanced stages (IVA—IVB) with different secondary/opportunistic diseases, among which was Burkitt’s lymphoma, a rather rare malignant disease that developed in obvious immunodeficiency in the absence of antiretroviral therapy.

References

  1. ВИЧ-инфекция и СПИД. Национальное руководство. Под ред. Покровского В.В. Краткое издание. М.: ГЭОТАР-Медиа; 2014.
  2. Хоффман К., Рокштро Ю.К. Лечение ВИЧ-инфекции 2009. М.: Р. Валент; 2010.
  3. Zoufaly A, Stellbrink HJ, der Heiden M. Insufficient virus suppression during HAART is a strong predictor for the development of AIDS-related lymphoma. Abstract 16, 15th CROI 2008, Boston.
  4. Levine AM. AIDS-related lymphoma: clinical aspects. Semin Oncol. 2000;27:442-453.
  5. Hoffmann C, Wolf E, Fatkenheuer G. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS. 2003;17:1521-1529.
  6. Lim ST, Karim R, Nathwani BN. AIDS-related Burkitt,s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23:4430-4438.

Statistics

Views

Abstract - 98

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2015 Mikhailova N.R., Ermak T.E., Anikeev A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies